Early efficacy and safety of adalimumab therapy in patients with Crohn's disease
Z Czegledi, P Miheller, T Szamosi, J Banai, Z Tulassay, O Gemela, J Papp, P Lakatos · Zeitschrift für Gastroenterologie · 2009 · Heft 05
Bibliografische Angaben
Zusammenfassung
Aims: Adalimumab is a fully human monoclonal antibody targeting tumor necrosis factor. We assess the early efficacy and frequency of side effects during induction and maintenance adalimumab therapy in patients with Crohn's disease. Methods: 54 CD patients were analyzed. (male/female: 34/20, mean age: 31.3 years, duration: 8.7 years). Indication for biologic therapy was steroid dependency and/or steroid refractory disease in 29 (53.7%) and fistulizing disease in 25 (46.3%) patients. Previous infliximab therapy was given in 20 (37%) patients. Concomitant immunosuppression was given to all patients (steroid 43 (79.…
